Navigation Links
Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
Date:11/19/2007

BEIJING, Nov. 19 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced an update on the clinical trials for its pandemic influenza vaccines. Sinovac received approval in April 2007 from the China State Food and Drug Administration (SFDA) to commence Phase Ib and II trials of its pandemic influenza (H5N1) whole viron inactivated vaccine and Phase I and II trials of its pandemic influenza (H5N1) split vaccine.

In the pandemic influenza whole viron vaccine Phase II trial, a total of 402 enrolled volunteers from 18 to 60 years old were vaccinated with doses of 5ug, 10ug or 15ug. In accordance with the Phase II trial protocol, all of the volunteers were vaccinated with two doses and followed for an observation period. There were no serious adverse events.

In the Phase I and Phase II trials for the split pandemic influenza vaccine, 160 volunteers from 3 to 70 years old, sorted into four different age groups, were enrolled. The volunteers received doses of 5ug, 10ug, 15ug or 30ug and were followed for an observation period. There were no serious adverse events.

Separately, Sinovac's external auditors are currently reviewing the Company's third quarter financial results, which the Company plans to disclose thereafter. Pertaining to the Annual General Meeting of Shareholders originally scheduled for August 2007, the Company did not receive at that time sufficient shareholder votes, given the geographical nature of its shareholders, to achieve a quorum, as per its corporate by-laws. Sinovac is diligently working to reschedule its Annual General Meeting.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and An
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
2. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
3. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Raptor Pharmaceuticals Provides Update of Product Programs
6. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
7. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
8. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
9. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
10. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
11. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... officer Howie Rosen will be presenting at ... Tim Morris will be presenting at JMP Securities ... as follows: Jefferies 2015 Healthcare Conference Date: ...
(Date:5/21/2015)... 21, 2015 Research and ... of the "Market Assessment of Respiratory Diagnostics ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This ... imaging diagnostics market in the United ... . The service provides detailed analysis of the ...
(Date:5/21/2015)... 2015 The Pharmaceutical Care Management Association ... Part D offsets included in the Energy & ... "If the 21st Century Cures initiative can only be ... program – Medicare – then its costs outweigh ... road. "Leveraging payments to Part D ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... Volcano Corporation (Nasdaq: VOLC ), a leading developer and ... treatment of coronary and peripheral vascular disease, said today that it will be ... 10 . , , , ... by Scott Huennekens , president and chief executive officer, will begin at ...
... YORK , Aug. 3 ITelagen, a leading provider of ... by Manhattan ,s Physician Group (MPG) to host, support and manage ... patient data in ITelagen,s SAS-70 Type II certified datacenter and an extension ... , , , ...
Cached Medicine Technology:Volcano Corporation Presentation at Canaccord Genuity Growth Conference to be Webcast 2Manhattan's Physicians Group Selects ITelagen for Hosting and Management of EHR 2Manhattan's Physicians Group Selects ITelagen for Hosting and Management of EHR 3
(Date:5/23/2015)... May 23, 2015 Injury lawyer Steven H. ... been passed by the Maryland legislature but which has not ... General Assembly passed HB 449 with overwhelming bipartisan ... not signed it into law. This bill ensures that fracking ... growing that demonstrates the danger of fracking to our water ...
(Date:5/22/2015)... 2015 The American College of Traditional ... June. They will hold a webinar on the updates ... class on Classical Chinese Medicine. , Webinar – First ... Given, the Dean of Clinical Education, will lead this ... Professional Doctorate program. ACTCM is currently developing this degree ...
(Date:5/22/2015)... 22, 2015 Hundreds of federal ... of individuals who allegedly experienced serious internal bleeding ... to move forward in the U.S. District Court, ... Order dated May 4, 2015, the Court has ... electronically stored information. Among other things, the Order ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow ... LaSalle D. Leffall, on Monday, May 18, with an ... Rounds in the hospital’s Tower Auditorium. Leffall’s younger sister, ... trying to keep the secret. “I’d like to go ... he’ll know something is up,” she said. , After ...
Breaking Medicine News(10 mins):Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... Ashley Judd will be here on a three-day visit to ... and maternal and child health.// ,The star of ... Crimes" will be visiting the Rajasthan capital as part of ... member of PSI (earlier known as Population Services International) and ...
... Australian scientists now look to honey as a solution, to fight ... Hospital in Middlesbrough were inspired by the use of honey by ... as a dressing for their wounds. , Mention of ... as the Charaka and Susrutha Samhitis, and the Bible as well. ...
... taken over as the Director General of Army's Medical Services ... College, Nagpur he was commissioned into the Army Medical Corps ... Pune University in 1977, he completed training in Radiation Oncology ... from Bombay University. ,A pioneer in the ...
... a pharmaceutical drug named Sunitinib in halting the ... of interferon and// sunitinib treatments found that sunitinib ... metastatic kidney cancer. ,The work was ... The New England Journal of Medicine and involved ...
... of the journal SLEEP finds that people with obstructive ... disease.// ,The study attributes the increased link ... a rising prevalence. Results suggest that OSA plays a ... hypertension. ,"There is abundant physiologic evidence ...
... could affect your judgment, suggests a new study.// ... affect brain function. Now William Killgore and colleagues at ... Spring, Maryland, US, studied 26 healthy adults, all of ... researchers found that sleep deprivation has a particularly debilitating ...
Cached Medicine News:Health News:A New Drug for Halting Metastatic Kidney Cancer 2Health News:Sleep Well, Have a Healthy Heart ! 2
... can choose either the PARI LC PLUS® or ... to both:, ,Maximize aerosol output when the ... patient exhales using two one-way valves. Baffles allow ... The result is a high percentage of particles ...
... with metered dose inhalers., ,ACE ensures ... MDI canisters. Its versatile design allows it ... in conjunction with an endotracheal airway or ... ACE may also be used in conjunction ...
... Kit Nebulizer Small Volume Medication W/Adult Mask ... Tubing Tee Adapter , ,An ... , ,Provide fine particles with a ... than conventional nebulizers, ,Our AirLife™ brand ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: